Sponsored content: Public-private partnerships can help prevent one of Canada’s biggest killers

Today is World Heart Day – a time to reflect and consider all that we can do for the health of every heart.

Cardiovascular disease (CVD) remains one of the leading causes of death in Canada. While in the world about 300 million people suffer from cardiovascular atherosclerosis disease (the main driver of cardiovascular disease), with an additional 2 billion people at risk.

Yet most don’t realize that approximately 80% of cardiovascular events, such as heart disease and stroke, are preventable..

As you can imagine, the ripple effect triggered by people affected by these conditions has caused a significant strain on our healthcare system. In Canada alone, CVD is estimated to cost us approximately $22 billion per year.

So how do we ease the burden of our strained system while working to improve the system itself?

To combat the impact of cardiovascular disease, we must focus on primary and secondary disease prevention. With CVD, we know the risk of a second incident is high. Thus, early detectionSurveillance and diagnosis are key to keeping people out of hospital and reducing the need for surgery. We also know that good data collection can support earlier diagnosis and treatment management and the ability to move forward with consistency. And that better data can harmonize our healthcare system and increase the efficiency of patient care. In short, we need to leverage data and data collection to move from being reactive to being proactive.

I believe that the only way to achieve this for the good of all Canadians is through public-private partnerships (P3s).

It’s no secret that throughout the COVID-19 pandemic, issues regarding the strain that chronic disease places on our system have only gotten worse. Experts call this convergence of mini-epidemics a “syndemic” — clusters of diseases that complicate treatment and prognosis. To better address these healthcare challenges, we need to rethink how we approach healthcare, and the good news is that we’ve already had a glimpse of what this brighter future of healthcare might hold for us.

Over the past 18 months, industry, governments and not-for-profit organizations have come together to find innovative ways to protect and treat Canadians. We must now apply the lessons learned from this collaborative approach across our healthcare system and build a new, more sustainable healthcare system focused on value and access for the future.

This reflection joins the Ontario Government’s Plan to Stay Open: Health System Stability and Recoverywhich is structured to help provide patients with the best care possible while ensuring the resources are in place to keep the province open – supporting a stronger, more resilient healthcare system.

The best and most effective way to achieve this is through public-private partnerships (PPPs). PPPs can transform current care systems into true health care systems that prioritize keeping people healthy rather than caring for them only when they are not feeling well.

At Novartis, we actively seek to address inequities in care, barriers to access, challenges and opportunities by investing in the best provincial teams. These teams foster innovative partnerships and collaboration at the health system level to address critical issues, such as cardiovascular disease. For example, from 2018 to 2021, nearly $3 million has been invested to establish heart failure optimization clinics to better improve patient care in Ontario.

Our goal in conducting these PPPs is to optimize healthcare solutions at the local level so that all patients can proactively seek out and access the care they need to help reduce the number of preventable cardio events. . But to make sure it’s done right, we need to partner with the right partners.

With that in mind, last year we launched the Biome Summit, an annual event that aims to break down silos in healthcare by bringing together public and private organizations to deliver real solutions. As the main topic of discussion, the Biome Summit places cardiovascular disease mortality at the forefront of public discourse, to serve as a catalyst for these impactful partnerships and concrete innovations to accelerate progress on this major challenge of health care in Canada.

We also work in partnership with healthcare system (HCS) decision makers around the world to reduce and stop premature deaths from cardiovascular disease by establishing PPPs that support the shift to more prevention-focused cardiovascular care delivery models. , efficient and fair. In the UK, for example, Novartis has established a first-of-its-kind PPP with the NHS, with the aim of achieving the UK’s goal of reducing up to 150,000 deaths from cardiovascular disease in the country in over the next 10 years. This partnership was based on investments to modernize the delivery of health care to better identify, treat and monitor people with heart disease through new models of optimization and data sharing and distribution intended to reach populations. in large scale.

We have also entered into partnerships with public healthcare systems around the world, with more planned for the future, including in Canada. These partnerships aim to work with provincial, local and community health systems to leverage data to improve CVD prevention, both primary and secondary, intervention effectiveness, SCS performance and digitization as well as investments in clinical research and examining how these programs can be scaled up quickly.

I strongly believe that we need to ignite people power, collaboration and knowledge sharing to drive meaningful and lasting change for Canadians as we tackle the toughest health issues. On this World Heart Day, I encourage public and private sector organizations to come together to help reduce the burden of cardiovascular disease on patients, while working to improve the healthcare system for every Canadian.

Andrea Marazzi, National President of Novartis Canada